Nippon Shokubai, JP3640200006

Nippon Shokubai starts Fol-Dab8 study before Nippon Shokubai stock results

Published on 10/20/2026 at 01:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nippon Shokubai invested in PURMX on September 29, 2026. For Nippon Shokubai stock, November 9 brings results after JPY 121.32 billion in first-quarter revenue.

Drug delivery and earnings calendar

Nippon Shokubai made one equity investment in PURMX on September 29, 2026.
First-quarter revenue reached JPY 121.32 billion against a JPY 110.25 billion estimate.
The next earnings report is scheduled for November 9, 2026.

Nippon Shokubai, JP3640200006, Illustration mit AI erstellt.

Nippon Shokubai (ISIN JP3640200006) made one equity investment in PURMX Therapeutics on September 29, 2026, alongside a joint study of Fol-Dab8, its drug delivery material. The company described the project in an official release from Nippon Shokubai.

Drug delivery becomes the latest catalyst

The study will test whether Fol-Dab8 can be combined with naturally occurring microRNA for oligonucleotide therapeutics. Nippon Shokubai said the investment amount and ownership stake will not be disclosed, keeping the announcement focused on technology development rather than near-term financial terms.

Fol-Dab8 is a folate-conjugated cationic peptide designed to target tissues with high folate receptor expression. The company is developing it through its healthcare business, which includes contract development and manufacturing services for oligonucleotide and peptide therapeutics.

What does the earnings gap mean?

TradingView reports that Nippon Shokubai's first-quarter fiscal 2027 revenue reached JPY 121.32 billion, versus a JPY 110.25 billion estimate, a 10.04 percent outperformance. Net income stood at JPY 10.38 billion, compared with JPY 2.39 billion in the previous quarter, according to TradingView.

The three most recent dated developments were August 7, 2026, when first-quarter revenue reached JPY 121.32 billion; September 19, 2026, when Nippon Shokubai was removed from the FTSE All-World Index; and September 29, 2026, when it began the Fol-Dab8 study and made one equity investment in PURMX. The index change was reported by Yahoo Finance.

Upcoming dates set the next test

The next substantiated date is November 9, 2026, for Nippon Shokubai's next earnings report, according to Nippon Shokubai. TradingView also lists November 9, 2026 as the next earnings date. The next ex-dividend date shown by Yahoo Finance is March 30, 2027.

Technology and earnings now define the story

Nippon Shokubai's latest announcement adds a healthcare application to a business whose first-quarter numbers already showed revenue above the estimate. The November report should clarify whether the JPY 10.38 billion first-quarter net income figure is the start of a broader earnings improvement or a period-specific result.